DexCom jumps 4% as CONNECT trial published in New England Journal of Medicine

DexCom shares rose 4% after its CONNECT trial was published in The New England Journal of Medicine, backing continuous glucose monitors for Type 2 diabetes patients not on insulin.

Detected & updated continuously · Source: Nebula